Neurocrine Biosciences Stock Price Target and Analyst Ratings (NASDAQ:NBIX)

Analyst Price Target for NBIX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$126.53

▲ +13.91% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for Neurocrine Biosciences in the last 3 months. The average price target is $126.53, with a high forecast of $149.00 and a low forecast of $90.00. The average price target represents a 13.91% upside from the last price of $111.08.

Buy

The current consensus among 19 contributing investment analysts is to buy stock in Neurocrine Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
13 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
10 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
11 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
12 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
11 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
11 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/29/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$168.00 ➝ $121.00	N/A	i
12/16/2020	Morgan Stanley	Lower Price Target	Overweight	$133.00 ➝ $121.00	Medium	i
12/7/2020	Wedbush	Lower Price Target	Outperform	$129.00 ➝ $121.00	High	i Rating by L. Chico at Wedbush
11/12/2020	Canaccord Genuity	Lower Price Target	Buy	$145.00 ➝ $122.00	Low	i
11/10/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Lower Price Target		$149.00 ➝ $138.00	Low	i
11/10/2020	Oppenheimer	Lower Price Target		$150.00 ➝ $145.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/10/2020	Smith Barney Citigroup	Lower Price Target		$149.00 ➝ $138.00	Low	i
11/10/2020	William Blair	Reiterated Rating	Outperform		Low	i
11/10/2020	Wedbush	Lower Price Target	Outperform	$147.00 ➝ $129.00	Medium	i Rating by L. Chico at Wedbush
11/10/2020	Credit Suisse Group	Lower Price Target	Neutral	$105.00 ➝ $90.00	High	i
11/10/2020	Mizuho	Lower Price Target	Neutral	$132.00 ➝ $117.00	High	i
11/10/2020	SVB Leerink	Lower Price Target	Market Perform	$120.00 ➝ $100.00	High	i
10/29/2020	Oppenheimer	Lower Price Target	Outperform	$155.00 ➝ $150.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
9/30/2020	Benchmark	Initiated Coverage	Hold		High	i
8/4/2020	Credit Suisse Group	Lower Price Target	Neutral	$135.00 ➝ $126.00	High	i
8/4/2020	Canaccord Genuity	Boost Price Target	Buy	$134.00 ➝ $145.00	High	i
8/4/2020	Morgan Stanley	Lower Price Target	Overweight	$149.00 ➝ $146.00	High	i
8/4/2020	HC Wainwright	Boost Price Target	Buy	$131.00 ➝ $140.00	High	i Rating by Andrew Fein at HC Wainwright
8/4/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$144.00 ➝ $161.00	High	i
8/4/2020	Mizuho	Boost Price Target	Neutral	$127.00 ➝ $132.00	High	i
8/4/2020	SVB Leerink	Boost Price Target	Market Perform	$105.00 ➝ $120.00	High	i
8/4/2020	Piper Sandler	Boost Price Target	Overweight	$141.00 ➝ $145.00	High	i Rating by David Amsellem at Piper Sandler
8/4/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$136.00	High	i
7/23/2020	Mizuho	Boost Price Target	Neutral	$105.00 ➝ $127.00	Medium	i Rating by Vamil Divan at Mizuho
7/20/2020	Credit Suisse Group	Boost Price Target	Neutral	$101.00 ➝ $135.00	Medium	i
7/17/2020	Oppenheimer	Boost Price Target	Outperform	$142.00 ➝ $152.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/15/2020	Morgan Stanley	Boost Price Target	Overweight	$120.00 ➝ $149.00	Low	i
6/29/2020	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$135.00	High	i
6/26/2020	Citigroup	Boost Price Target	Buy	$124.00 ➝ $149.00	High	i Rating by Neena Bitritto-Garg at Citigroup Inc.
6/18/2020	JPMorgan Chase & Co.	Boost Price Target	In-Line ➝ Overweight	$122.00 ➝ $134.00	Medium	i
6/18/2020	Royal Bank of Canada	Boost Price Target	Outperform	$116.00 ➝ $135.00	Low	i
6/17/2020	HC Wainwright	Reiterated Rating	Buy	$125.00 ➝ $131.00	Low	i Rating by A. Fein at HC Wainwright
6/16/2020	Needham & Company LLC	Initiated Coverage	Hold		Low	i Rating by Alan Carr at Needham & Company LLC
6/16/2020	Oppenheimer	Initiated Coverage	Buy	$142.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
6/10/2020	Canaccord Genuity	Boost Price Target	Buy	$123.00 ➝ $134.00	Low	i
6/8/2020	Wedbush	Initiated Coverage	Outperform	$147.00	Low	i Rating by L. Chico at Wedbush
6/1/2020	Piper Sandler	Reiterated Rating	Buy	$126.00	Low	i Rating by David Amsellem at Piper Sandler
5/7/2020	Canaccord Genuity	Boost Price Target	Buy	$122.00 ➝ $123.00	High	i
5/7/2020	Barclays	Boost Price Target	Equal Weight	$105.00 ➝ $108.00	High	i
5/7/2020	Mizuho	Boost Price Target	Neutral	$103.00 ➝ $105.00	High	i Rating by Vamil Divan at Mizuho
5/7/2020	Morgan Stanley	Lower Price Target	Buy	$121.00 ➝ $120.00	High	i
5/7/2020	HC Wainwright	Reiterated Rating	Buy	$125.00	High	i Rating by A. Fein at HC Wainwright
5/7/2020	Needham & Company LLC	Reiterated Rating	Hold		High	i Rating by Alan Carr at Needham & Company LLC
4/30/2020	William Blair	Reiterated Rating	Buy		High	i Rating by M. Minter at William Blair
4/27/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium	i
4/13/2020	Oppenheimer	Lower Price Target	Outperform	$132.00 ➝ $130.00	Low	i
4/8/2020	Piper Sandler	Lower Price Target		$147.00 ➝ $125.00	Medium	i
4/8/2020	Needham & Company LLC	Reiterated Rating	Hold ➝ Neutral		Medium	i
4/8/2020	Royal Bank of Canada	Reiterated Rating	Buy	$104.00	Medium	i
3/5/2020	Citigroup	Initiated Coverage	Buy	$124.00	Medium	i
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$105.00	High	i
2/24/2020	William Blair	Initiated Coverage	Outperform	$116.00	High	i Rating by M. Minter at William Blair
2/14/2020	Stifel Nicolaus	Reiterated Rating	Buy	$127.00	N/A	i Rating by Paul Matteis at Stifel Nicolaus
2/5/2020	Mizuho	Initiated Coverage	Neutral	$107.00	Low	i
2/5/2020	HC Wainwright	Reiterated Rating	Buy	$102.00 ➝ $125.00	Medium	i
1/20/2020	Royal Bank of Canada	Reiterated Rating	Buy	$125.00	Low	i Rating by Brian Abrahams at Royal Bank of Canada
1/17/2020	Morgan Stanley	Boost Price Target	Overweight	$120.00 ➝ $121.00	Medium	i
1/13/2020	Oppenheimer	Boost Price Target	Outperform	$115.00 ➝ $132.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/17/2019	Morgan Stanley	Boost Price Target	Overweight	$110.00 ➝ $120.00	Medium	i
12/13/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$110.00	Low	i
12/12/2019	Piper Jaffray Companies	Reiterated Rating	Overweight	$116.00 ➝ $153.00	Medium	i
11/5/2019	Piper Jaffray Companies	Boost Price Target		$111.00 ➝ $116.00	Low	i
9/6/2019	Royal Bank of Canada	Set Price Target	Buy	$118.00	Medium	i Rating by Brian Abrahams at Royal Bank of Canada
8/7/2019	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$118.00	Low	i
7/31/2019	Needham & Company LLC	Reiterated Rating	Hold		Medium	i
7/30/2019	Credit Suisse Group	Boost Price Target	Outperform	$95.00 ➝ $110.00	High	i
7/30/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$103.00 ➝ $111.00	High	i
7/16/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$100.00	Low	i
7/16/2019	Oppenheimer	Initiated Coverage	Outperform	$100.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/15/2019	Stifel Nicolaus	Set Price Target	Buy	$113.00	Low	i Rating by Paul Matteis at Stifel Nicolaus
6/4/2019	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$88.00	Medium	i
5/20/2019	Credit Suisse Group	Initiated Coverage	Outperform	$95.00	Medium	i
4/22/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$100.00 ➝ $106.00	High	i
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		Low	i
3/29/2019	Barclays	Reiterated Rating	Buy	$110.00	High	i
3/13/2019	Oppenheimer	Boost Price Target	Outperform	$105.00 ➝ $110.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/6/2019	Bank of America	Lower Price Target	Buy	$124.00 ➝ $117.00	Medium	i
2/6/2019	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by Charles Duncan at Cantor Fitzgerald
1/30/2019	HC Wainwright	Reiterated Rating	Buy		Medium	i
1/29/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$121.00	Medium	i Rating by Charles Duncan at Cantor Fitzgerald
1/29/2019	Oppenheimer	Set Price Target	Buy	$105.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/24/2019	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low	i Rating by Alan Carr at Needham & Company LLC
1/23/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$97.00 ➝ $100.00	Medium	i
1/15/2019	HC Wainwright	Reiterated Rating	Buy	$102.00	High	i
1/6/2019	Oppenheimer	Set Price Target	Buy	$105.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/13/2018	Oppenheimer	Lower Price Target	Outperform	$140.00 ➝ $105.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/13/2018	JPMorgan Chase & Co.	Lower Price Target	Overweight	$127.00 ➝ $97.00	Low	i
12/13/2018	Robert W. Baird	Lower Price Target	Outperform	$131.00 ➝ $96.00	Medium	i
12/13/2018	SVB Leerink	Lower Price Target	Market Perform	$110.00 ➝ $84.00	Medium	i Rating by M. Goodman at SVB Leerink LLC
12/13/2018	Canaccord Genuity	Lower Price Target	Buy	$111.00 ➝ $100.00	Medium	i
12/13/2018	HC Wainwright	Reiterated Rating	Buy	$162.00	Medium	i
12/13/2018	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$103.00	Medium	i Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/13/2018	Barclays	Reiterated Rating	Buy	$95.00	Medium	i
12/12/2018	Stifel Nicolaus	Lower Price Target	Buy	$115.00 ➝ $17.07	High	i
12/12/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$121.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
12/12/2018	Needham & Company LLC	Set Price Target	Buy	$104.00	High	i Rating by Alan Carr at Needham & Company LLC
12/11/2018	Oppenheimer	Set Price Target	Buy	$140.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
12/5/2018	Cantor Fitzgerald	Set Price Target	Buy	$150.00	Low	i Rating by Charles Duncan at Cantor Fitzgerald
11/21/2018	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$111.00	Low	i
11/12/2018	SVB Leerink	Initiated Coverage	Market Perform	$110.00	High	i Rating by M. Goodman at SVB Leerink LLC
11/6/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Buy	$145.00 ➝ $135.00	Low	i Rating by Jeffrey Hung at Morgan Stanley
11/6/2018	Piper Jaffray Companies	Set Price Target	Buy	$111.00	High	i Rating by David Amsellem at Piper Jaffray Companies
11/5/2018	Cantor Fitzgerald	Set Price Target	Buy	$150.00	High	i Rating by Charles Duncan at Cantor Fitzgerald
11/5/2018	Oppenheimer	Set Price Target	Buy	$140.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
10/5/2018	Piper Jaffray Companies	Set Price Target	Buy	$115.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
9/20/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$137.00 ➝ $142.00	Low	i
9/20/2018	Cantor Fitzgerald	Set Price Target	Buy	$150.00	Low	i Rating by Charles Duncan at Cantor Fitzgerald
9/14/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$150.00	Low	i Rating by Charles Duncan at Cantor Fitzgerald
9/12/2018	Oppenheimer	Set Price Target	Buy	$140.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
9/10/2018	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight	$145.00	Medium	i
9/4/2018	ICAP	Lower Price Target	Outperform	$140.00 ➝ $128.00	Medium	i
9/4/2018	Oppenheimer	Set Price Target	Buy	$140.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/22/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$150.00	Low	i Rating by C. Duncan at Cantor Fitzgerald
8/7/2018	Stifel Nicolaus	Initiated Coverage	Buy	$137.00	Low	i
8/1/2018	Needham & Company LLC	Set Price Target	Buy	$125.00	Low	i Rating by Alan Carr at Needham & Company LLC
8/1/2018	HC Wainwright	Reiterated Rating	Buy	$162.00	High	i
8/1/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $135.00	High	i Rating by Geoff Meacham at Barclays PLC
7/31/2018	Oppenheimer	Set Price Target	Buy	$128.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/30/2018	Jefferies Financial Group	Boost Price Target	Buy	$124.00	High	i
7/25/2018	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$100.00 ➝ $122.00	High	i
7/16/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight	$127.00	Medium	i
6/8/2018	Barclays	Set Price Target	Buy	$100.00	Low	i Rating by Geoff Meacham at Barclays PLC
5/14/2018	Oppenheimer	Set Price Target	Buy	$120.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/7/2018	Cowen	Reiterated Rating	Buy	$100.00	Low	i
5/1/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$101.00 ➝ $102.00	High	i
5/1/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy ➝ Buy	$97.00 ➝ $99.00	High	i Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/1/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$100.00 ➝ $103.00	High	i
5/1/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$84.00 ➝ $100.00	High	i
4/10/2018	Oppenheimer	Set Price Target	Buy	$110.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
3/21/2018	Oppenheimer	Reiterated Rating	Buy		Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
3/14/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$113.00	Medium	i Rating by Charles Duncan at Piper Jaffray Companies
3/13/2018	Oppenheimer	Set Price Target	Buy	$110.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/22/2018	Oppenheimer	Set Price Target	Buy	$110.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/22/2018	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $110.00	Low	i
2/20/2018	SVB Leerink	Boost Price Target	Outperform	$90.00 ➝ $96.00	Medium	i
2/14/2018	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$97.00	Medium	i
2/14/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$79.00 ➝ $100.00	High	i
2/14/2018	Barclays	Reiterated Rating	Overweight	$100.00	High	i
2/14/2018	Oppenheimer	Set Price Target	Buy	$95.00 ➝ $100.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/16/2018	Needham & Company LLC	Boost Price Target	Buy	$95.00	High	i
1/15/2018	Oppenheimer	Set Price Target	Buy	$85.00 ➝ $95.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/5/2018	Jefferies Financial Group	Boost Price Target	Buy	$105.00	Medium	i
12/12/2017	Oppenheimer	Set Price Target	Buy	$85.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/14/2017	Oppenheimer	Set Price Target	Buy	$85.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/3/2017	Robert W. Baird	Reiterated Rating	Buy	$84.00	N/A	i
11/2/2017	Needham & Company LLC	Reiterated Rating	Buy	$86.00	N/A	i
11/2/2017	Barclays	Boost Price Target	Overweight	$75.00 ➝ $85.00	N/A	i
11/2/2017	Oppenheimer	Boost Price Target	Outperform	$70.00 ➝ $85.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
11/2/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$79.00	N/A	i
11/2/2017	BMO Capital Markets	Boost Price Target	Positive ➝ Outperform	$83.00 ➝ $109.00	N/A	i
11/2/2017	SVB Leerink	Reiterated Rating	Outperform	$72.00 ➝ $83.00	N/A	i
11/2/2017	Citigroup	Reiterated Rating	Buy	$79.00	N/A	i
10/25/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$76.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
10/10/2017	SVB Leerink	Reiterated Rating	Outperform	$67.00 ➝ $72.00	N/A	i
10/5/2017	BMO Capital Markets	Reiterated Rating	Outperform	$84.00	N/A	i
10/3/2017	Jefferies Financial Group	Reiterated Rating	Buy	$66.00 ➝ $69.00	Low	i
9/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$66.00	High	i
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$58.00	Low	i
9/7/2017	Oppenheimer	Reiterated Rating	Buy	$70.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
8/24/2017	Piper Jaffray Companies	Set Price Target	Buy	$68.00	Medium	i Rating by Charles Duncan at Piper Jaffray Companies
8/9/2017	Cowen	Reiterated Rating	Outperform	$60.00 ➝ $65.00	Medium	i
8/4/2017	BMO Capital Markets	Boost Price Target	Outperform	$75.00 ➝ $84.00	Low	i
7/5/2017	Oppenheimer	Reiterated Rating	Outperform	$70.00	Low	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/30/2017	Jefferies Financial Group	Reiterated Rating	Buy	$66.00	Low	i
5/25/2017	BMO Capital Markets	Reiterated Rating	Outperform	$75.00	Low	i
5/25/2017	SVB Leerink	Lower Price Target	Outperform	$68.00 ➝ $66.00	Low	i
5/24/2017	Oppenheimer	Set Price Target	Buy	$70.00	Medium	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/24/2017	Piper Jaffray Companies	Set Price Target	Buy	$68.00	Medium	i Rating by Charles Duncan at Piper Jaffray Companies
5/24/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$57.00	Medium	i Rating by Anupam Rama at JPMorgan Chase & Co.
5/24/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00 ➝ $58.00	Low	i
5/22/2017	Jefferies Financial Group	Reiterated Rating	Buy	$67.00	Medium	i
5/15/2017	Bank of America	Reiterated Rating	Buy	$70.00	Medium	i
5/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$67.00	Medium	i
5/5/2017	Bank of America	Initiated Coverage	Buy ➝ Buy	$70.00	Low	i
5/2/2017	Barclays	Boost Price Target	Overweight	$60.00 ➝ $70.00	Low	i
5/1/2017	Jefferies Financial Group	Boost Price Target	Buy	$65.00 ➝ $67.00	Medium	i
4/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Low	i
4/17/2017	BMO Capital Markets	Reiterated Rating	Outperform	$72.00	Low	i
4/17/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$80.00	Low	i Rating by Charles Duncan at Piper Jaffray Companies
4/14/2017	Robert W. Baird	Reiterated Rating	Outperform	$66.00	N/A	i Rating by Brian Skorney at Robert W. Baird
4/12/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$60.00	Medium	i Rating by Anupam Rama at JPMorgan Chase & Co.
4/12/2017	Jefferies Financial Group	Boost Price Target	Buy	$59.00 ➝ $65.00	High	i
4/8/2017	Oppenheimer	Set Price Target	Buy	$60.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
4/4/2017	Jefferies Financial Group	Reiterated Rating	Buy	$58.00	High	i
3/27/2017	Barclays	Reiterated Rating	Overweight	$60.00	Low	i
3/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Low	i
3/7/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$80.00	N/A	i
3/7/2017	Piper Jaffray Companies	Reiterated Rating	Outperform	$80.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
2/16/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	N/A	i
2/16/2017	HC Wainwright	Boost Price Target	Positive	$80.00 ➝ $100.00	N/A	i
2/15/2017	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
2/15/2017	Robert W. Baird	Reiterated Rating	Outperform	$66.00	N/A	i Rating by Brian Skorney at Robert W. Baird
2/14/2017	Oppenheimer	Set Price Target	Buy	$60.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/10/2017	Oppenheimer	Reiterated Rating	Outperform	$55.00 ➝ $55.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
2/10/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	N/A	i
2/10/2017	ICAP	Reiterated Rating	Outperform	$55.00	N/A	i
2/10/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
2/9/2017	SVB Leerink	Reiterated Rating	Outperform	$65.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
1/30/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
1/27/2017	CIBC	Upgrade	Market Perform ➝ Outperform		N/A	i
1/27/2017	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$55.00	N/A	i Rating by Jay Olson at Oppenheimer Holdings Inc.
1/19/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy	$65.00 ➝ $62.00	N/A	i
1/19/2017	BMO Capital Markets	Reiterated Rating	Outperform	$72.00	N/A	i
1/18/2017	Cowen	Set Price Target	Buy	$65.00	N/A	i Rating by Phil Nadeau at Cowen Inc
1/18/2017	HC Wainwright	Reiterated Rating	Buy		N/A	i
1/18/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	N/A	i
1/18/2017	Jefferies Financial Group	Lower Price Target	Buy	$61.00 ➝ $56.00	N/A	i
1/18/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
1/18/2017	Robert W. Baird	Reiterated Rating	Outperform	$66.00	N/A	i Rating by Brian Skorney at Robert W. Baird
1/15/2017	Oppenheimer	Reiterated Rating	Market Perform	$55.00	N/A	i
1/9/2017	Needham & Company LLC	Reiterated Rating	Buy	$62.00	N/A	i
1/8/2017	Robert W. Baird	Reiterated Rating	Buy	$66.00	N/A	i Rating by Brian Skorney at Robert W. Baird
1/8/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
12/23/2016	SVB Leerink	Reiterated Rating	Outperform	$70.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
12/7/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
11/22/2016	Oppenheimer	Initiated Coverage	Market Perform	$55.00	N/A	i
11/22/2016	Citigroup	Initiated Coverage	Market Perform	$55.00	N/A	i
11/8/2016	Jefferies Financial Group	Reiterated Rating	Sell	$61.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
11/3/2016	BMO Capital Markets	Reiterated Rating	Buy	$72.00	N/A	i
11/3/2016	Barclays	Reiterated Rating	Buy	$60.00	N/A	i
11/3/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
11/3/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$65.00	N/A	i
10/27/2016	BMO Capital Markets	Reiterated Rating	Outperform	$66.00 ➝ $72.00	N/A	i
10/18/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
10/18/2016	Needham & Company LLC	Initiated Coverage	Buy	$62.00	N/A	i
10/13/2016	BMO Capital Markets	Reiterated Rating	Outperform	$66.00	N/A	i
10/12/2016	SVB Leerink	Reiterated Rating	Outperform	$70.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
10/11/2016	Piper Jaffray Companies	Set Price Target	Buy	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
10/4/2016	SVB Leerink	Initiated Coverage	Outperform	$70.00	N/A	i Rating by P. Matteis at SVB Leerink LLC
9/23/2016	BMO Capital Markets	Reiterated Rating	Outperform	$66.00	N/A	i
9/23/2016	Jefferies Financial Group	Reiterated Rating	Buy	$61.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
9/22/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
8/30/2016	Robert W. Baird	Reiterated Rating	Outperform	$66.00	N/A	i Rating by Brian Skorney at Robert W. Baird
8/5/2016	Cowen	Reiterated Rating	Buy	$65.00	N/A	i Rating by Phil Nadeau at Cowen Inc
8/5/2016	HC Wainwright	Reiterated Rating	Buy		N/A	i Rating by Andrew Fein at HC Wainwright
6/29/2016	HC Wainwright	Initiated Coverage	Buy	$80.00	N/A	i
6/8/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
6/7/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
6/1/2016	SVB Leerink	Reiterated Rating	Outperform	$63.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC
5/25/2016	Jefferies Financial Group	Reiterated Rating	Buy	$61.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
5/19/2016	Jefferies Financial Group	Reiterated Rating	Buy	$58.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
5/16/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
5/8/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
5/8/2016	Robert W. Baird	Reiterated Rating	Buy		N/A	i Rating by Brian Skorney at Robert W. Baird
5/4/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
4/14/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
4/12/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
4/12/2016	BMO Capital Markets	Reiterated Rating	Outperform	$57.00	N/A	i
4/6/2016	BMO Capital Markets	Initiated Coverage	Outperform		N/A	i
4/4/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
3/28/2016	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	N/A	i Rating by Biren Amin at Jefferies Financial Group Inc.
2/12/2016	Cowen	Reiterated Rating	Buy	$65.00	N/A	i Rating by Phil Nadeau at Cowen Inc
2/11/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$96.00	N/A	i Rating by Charles Duncan at Piper Jaffray Companies
2/9/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$70.00 ➝ $63.00	N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
1/22/2016	SVB Leerink	Reiterated Rating	Buy	$71.00 ➝ $76.00	N/A	i Rating by Paul Matteis at SVB Leerink LLC

(Data available from 1/20/2016 forward)

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL Â- Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $111.08

$108.01

$111.75

50 Day Range

MA: $99.79

$90.21

$112.32

52 Week Range

Now: $111.08

$72.14

$136.26

Volume

680,667 shs

Average Volume

1,007,070 shs

Market Capitalization

$10.38 billion

P/E Ratio

119.44

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

The following Wall Street sell-side analysts have issued research reports on Neurocrine Biosciences in the last twelve months: Barclays PLC, Benchmark Co., Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wedbush, William Blair, and Zacks Investment Research.

What is the current price target for Neurocrine Biosciences?

19 Wall Street analysts have set twelve-month price targets for Neurocrine Biosciences in the last year. Their average twelve-month price target is $126.53, suggesting a possible upside of 16.3%. Citigroup Inc. has the highest price target set, predicting NBIX will reach $149.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $90.00 for Neurocrine Biosciences in the next year.

What is the current consensus analyst rating for Neurocrine Biosciences?

Neurocrine Biosciences currently has 8 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBIX will outperform the market and that investors should add to their positions of Neurocrine Biosciences.

What other companies compete with Neurocrine Biosciences?

Other companies that are similar to Neurocrine Biosciences include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Repligen, Ionis Pharmaceuticals, Novavax and United Therapeutics.

How do I contact Neurocrine Biosciences' investor relations team?

Neurocrine Biosciences' physical mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company's listed phone number is 858-617-7600 and its investor relations email address is ir@neurocrine.com. The official website for Neurocrine Biosciences is www.neurocrine.com.

NASDAQ:NBIX - Neurocrine Biosciences Stock Price Target and Predictions

Analyst Price Target for NBIX

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Neurocrine Biosciences?

What is the current price target for Neurocrine Biosciences?

What is the current consensus analyst rating for Neurocrine Biosciences?

What other companies compete with Neurocrine Biosciences?

How do I contact Neurocrine Biosciences' investor relations team?